Log in | Register

New therapeutic approaches in sepsis: A critical review

L. A. Eidelman| R. Pizov| C. L. Sprung
Original
Volume 21, Issue 2 / November , 1995

Pages S269 - S272

Abstract

This paper reviews several recent, randomized, double-blind, placebo-controlled trials of monoclonal antibodies against endotoxin, interleukin-1 receptor antagonist (IL-1 ra), and monoclonal antibody against tumor necrosis factor (TNF) in sepsis.

Keywords

References

  1. Sprung CL, Caralis PV, Marcial EH et al (1984) The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 311:1137–1143
  2. Bone RC, Fisher CJ Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med 317:653–658
  3. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effects of high-dose glucocorticoid therapy of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665
  4. Ziegler EJ, McCutchan JA, Fierer J et al (1987) Treatment of gram-negative bacteremia and shock with human antiserum to a mutantEscherichia coli. N Engl J Med 307:1225–1290.
  5. Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436
  6. Greenman RL, Schein RMH, Martin MA et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 266: 1097–1102
  7. Wenzel R, Bone R, Fein A et al (1991) Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody E 5 in Gram negative sepsis. In: Program and Abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy. 29 September–2 October, Chicago: 294
  8. Fisher CJ, Dhainaut JFA, Opal SM et al (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836–1843
  9. McCloskey RV, Straube RC, Sanders C et al (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1–5
  10. Wherry J, Wenzel R, Wunderink R et al (1993) Monoclonal antibody to human tumor necrosis factor (TNF MAb): multi-center efficacy and safety study in patients with the sepsis syndrome. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orelans, 17–20 October 1993, Washington, D. C.: American Sciety for Microbiology: 696, abstract
  11. Baumgartner JD, Glauser MP, McCutchan JA et al (1985) Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet II:59–63
  12. Calandra T, Glauser MP, Schellekens J et al (1988) Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J 5: A prospective, double-blind, randomized trial. J Infect Dis 158:312–319
  13. Dunn DL, Ewald DC, Chandan N et al (1986) Immunotherapy of Gram-negative bacterial sepsis: A single murine monoclonal antibody provides crossgenera protection. Arch Surg 121: 58–62
  14. Teng NNH, Kaplan HS, Herbert JM et al (1985) Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794
  15. Wortel CH, von der Mohlen MAM, van Deventer SJH et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (Ha-1A) in Gram-negative sepsis. Relationship to endotoxin and cytokine levels. J Infect Dis 166: 1367–1374
  16. Siegel JP, Stein KE, Zoon KC (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 327:890–891
  17. Fisher CJ Jr, Slotman GJ, Opal SM et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled, multicenter trial. Crit Care Med 22:12–21
  18. Eidelman LA, Sprung CL (1994) Why have new effictive therapies for sepsis not been developed? Crit Care Med 22: 1330–1334

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement